Unilever share price today: ULVR edges higher near 5,070p ahead of Feb 12 results

Unilever share price today: ULVR edges higher near 5,070p ahead of Feb 12 results

London, Feb 4, 2026, 08:32 GMT — Regular session

  • Unilever shares edged up in early London trading, building on gains from the past two days.
  • A standard voting-rights filing shifted attention to disclosure details rather than core issues.
  • Traders are focused on the Bank of England’s decision Thursday and Unilever’s upcoming earnings next week.

Unilever (ULVR.L) shares climbed 0.4% to 5,066 pence by 0817 GMT, after starting the day at 5,033 pence and fluctuating between 5,031 and 5,069 so far this Wednesday. The stock closed Tuesday at 5,045 pence, marking a 1.1% gain for the day. (Share Prices)

The steady rise follows a sharp selloff in AI-exposed UK stocks that knocked the FTSE 100 off an intraday record on Tuesday. “Risk appetite just isn’t fully restored,” said Ipek Ozkardeskaya, senior analyst at Swissquote Bank, highlighting recent volatility in commodity-linked shares. (Reuters)

Sterling assets kept attracting buyers this week, pushing London’s blue-chip index to a record close on Monday. The surge came as investors shifted into defensive stocks, typically favored for their steadier earnings amid uncertain growth. Ozkardeskaya noted the move “reflected improving global risk sentiment,” despite ongoing volatility in commodities. (Reuters)

Unilever provided scant new information internally. In a regulatory filing on Monday, the company reported its issued share capital at 2,181,005,247 ordinary shares as of Jan. 30. Of these, 2,180,690,335 shares carried voting rights, excluding a minor block held within the group. (TradingView)

Shareholders use these “total voting rights” statements as the denominator to determine if they must disclose stakes or changes under UK regulations. Usually, they fly under the radar unless they hint at a major capital move.

Unilever’s next major event hits on Feb. 12, when it will release fourth-quarter and full-year 2025 earnings. Then on Feb. 17, the company is scheduled to take the stage at the CAGNY consumer conference, offering another key moment for investor updates. (Unilever)

Investors want a clear signal on whether volume is picking up or if sales are still driven by price. This matters as shoppers stay wary of rising grocery costs and retailers intensify promotional efforts.

Unilever’s lineup places it firmly in the global consumer staples category, competing with names like Nestlé and Procter & Gamble. Investors typically focus on familiar metrics: volume trends, pricing strength, and whether rising costs are starting to squeeze margins once more.

That said, the setup isn’t foolproof. Should Unilever signal weaker margins, heavier discounting, or softer demand in key markets, the recent rally could unravel fast—especially if broader risk appetite sours once more.

Traders are focused on Thursday’s Bank of England decision, scanning for any changes in the interest rate outlook. Attention will then turn to Unilever’s Feb. 12 earnings, which could reshape forecasts for 2026.

Stock Market Today

  • Microsoft Shares Bought by Representative David Taylor Amid Strong Earnings
    February 4, 2026, 3:56 AM EST. Representative David Taylor (R-Ohio) recently purchased between $1,001 and $15,000 in Microsoft shares in January 2026, disclosed on February 2nd. Microsoft (NASDAQ:MSFT) opened at $411.21 with a market cap of $3.05 trillion. The company reported strong quarterly earnings on January 28, beating estimates with $4.14 EPS and $81.27 billion revenue, up 16.7% year-over-year. Microsoft also announced a quarterly dividend of $0.91 per share, yielding 0.9%, payable March 12. The stock trades near its 50-day average of $473.51 and 200-day average of $498.30. Institutional investors like WFA Asset Management increased stakes by 27% in Q1. Taylor's moves include purchases of Broadcom, Amazon, Salesforce, and sales of Amgen and Procter & Gamble, reflecting diversified stock activity.
GSK beats 2025 sales targets — but new CEO warns 2026 growth will cool
Previous Story

GSK beats 2025 sales targets — but new CEO warns 2026 growth will cool

Go toTop